U.S. ready to help China on COVID-19 surge if Beijing asks — White House
FILE PHOTO: Pandemic prevention workers in protective suits cross a street as coronavirus disease (COVID-19) outbreaks continue in Beijing, December 9, 2022. REUTERS/Thomas Peter
PFE
+2.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
KEX
-0.38%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
WASHINGTON (Reuters) — The United States is prepared to help China deal with a surge of COVID-19 infections if Beijing requests assistance, the White House said on Wednesday.
John Kirby (NYSE:KEX), the White House national security spokesperson, told reporters that China has not requested help at this stage.
«We have made that point that we are prepared to help in any way they might find acceptable. That was true back when the pandemic was raging, and that is true today,» Kirby told reporters.
White House national security adviser Jake Sullivan told reporters earlier this week that U.S. and Chinese officials had discussed COVID-19 and countries’ different response to the pandemic were discussed at U.S.-Chinese meetings, but gave no details.
«I want to give an opportunity for us to be able to have those conversations in sensitive diplomatic channels. And we’ll see what, if anything, comes out of it,» he said.
China Meheco Group Co Ltd said on Wednesday it signed an agreement with U.S. drugmaker Pfizer Inc (NYSE:PFE) to import and distribute its oral COVID-19 treatment Paxlovid in mainland China, as the country braces for a surge in patients after scaling back its «zero COVID» policy.
Pfizer already signed a deal in August for Chinese drugmaker Zhejiang Huahai
